The efficacy of ritonavir in the prevention of aids-related Kaposi's sarcoma

International Journal of Cancer

Volumn 108, Issue 4, 2004, Pages 631-633

  Stebbing, Justin ^a   Portsmouth, Simon ^a   Nelson, Mark ^a   Mandalia, Sundhiya ^a   Kandil, Hala ^a   Alexander, Nic ^a   Davies, Liz ^a   Brock, Cathryn ^a   Bower, Mark ^a   Gazzard, Brian ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis; Cohort study; Kaposi's sarcoma; Protease inhibitor; Ritonavir

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANGIOGENESIS; ARTICLE; CHEMOPROPHYLAXIS; COHORT ANALYSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SPECIFICITY; HUMAN; IMMUNE FUNCTION TEST; KAPOSI SARCOMA; LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; PROPHYLAXIS; REGRESSION ANALYSIS;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; SARCOMA, KAPOSI; TREATMENT OUTCOME;

EID: 9144254482     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11648     Document Type: Article

References (31)

1. Stebbing J, Portsmouth S, Bower M. Insights into the molecular biology and sero-epidemiology of Kaposi's sarcoma. Curr Opin Infect Dis 2003;16:25-31.
2. Stebbing J, Portsmouth S, Gotch F, Gazzard B. Kaposi's sarcoma - an update. Int J STD AIDS 2003;14:225-7.
3. Bower M, Fox P, Fife K, Gill J, Nelson M, Gazzard B. Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma. AIDS 1999;13:2105-11.
4. Jacobson LP, Yamashita TE, Detels R, Margolick JB, Chmiel JS, Kingsley LA, Melnick S, Munoz A. Impact of potent anti-retroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1 infected individuals. Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 1999;21(Suppl 1):s34-41.
5. International collaboration on HIV and cancer: highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000;92:1823-30.
6. Portsmouth S, Stebbing J, Gill J, Mandalia S, Bower M, Nelson M, Gazzard B. A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma. AIDS 2003;17:F17-22.
7. Stebbing J, Portsmouth S, Gazzard B. How does HAART lead to the resolution of Kaposi's sarcoma? J Antimicrob Chemother 2003;51:1095-8.
8. Stebbing J, Bourloulia D, Johnson M, Henderson S, Williams I, Wilder N, Tyrer M, Youle M, Imami N, Kobu T, Kuon W, Sieper J, Gotch F, et al. Kaposi's sarcoma-associated herpesvirus cytotoxic T lymphocytes recognize and target Darwinian positively selected autologous K1 epitopes. J Virol 2003;77:4306-14.
9. Sirianni MC, Vincenzi L, Topino S, Giovannetti A, Mazzetta F, Libi F, Scaramuzzi D, Andreoni M, Pinter E, Baccarini S, Rezza G, Monimi P, et al. NK cell activity controls human herpesvirus 8 latent infection and is restored upon highly active antiretroviral therapy in AIDS patients with regressing Kaposi's sarcoma. Eur J Immunol 2002;32:2711-20.
10. Ensoli B, Barillari G, Salahuddin SZ, Gallo RC, Wong-Staal F. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature 1990;345:84-6.
11. Ensoli B, Gendelman R, Markham P, Fiorelli V, Colombini S, Raffeld M, et al. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature 1994;371:674-80.
12. Kedes DH, Ganem D. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J Clin Invest 1997;99:2082-6.
13. Gill J, Bourboulia D, Wilkinson J, Hayes P, Cope A, Marcelin AG, Gazzard B, Gotch F. Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma - associated herpesvirus infection in patients with and without Kaposi sarcoma. J Acquir Immune Defic Syndr 2002;31:384-90.
14. Fiorelli V, Gendelman R, Samaniego F, Markham PD, Ensoli B. Cytokines from activated T cells induce normal endothelial cells to acquire the phenotypic and functional features of AIDS-Kaposi's sarcoma spindle cells. J Clin Invest 1995;95:1723-34.
15. Fiorelli V, Barillari G, Toschi E, Sgadari C, Monini P, Sturzl M, Ensoli B. IFN-gamma induces endothelial cells to proliferate and to invade the extracellular matrix in response to the HIV-1 Tat protein: implications for AIDS-Kaposi's sarcoma pathogenesis. J Immunol 1999;162:1165-70.
16. Conant MA, Opp KM, Poretz D, Mills RG. Reduction of Kaposi's sarcoma lesions following treatment of AIDS with ritonavir. AIDS 1997;11:1300-1.
17. Lebbe C, Blum L, Pellet C, Blanchard G, Verola O, Morel P, Danne O, Calvo F. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma. AIDS 1998;12:F45-9.
18. Sgadari C, Barillari G, Toschi E, Carlei D, Bacigalupo I, Baccarini S, Palladino C, Leone P, Bugarini R, Malavasi L, Cafaro A, Falchi M, et al. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med 2002;8:225-32.
19. Pati S, Pelser CB, Dufraine J, Bryant JL, Reitz Jr MS, Weichold FF. Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma. Blood 2002;99:3771-9.
20. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2001;2:276-313.
21. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002;288:222-35.
22. Palella Jr FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60.
23. Plosker G, Scott L, Chíeco-Bianchi L, Saquinavir. A review of its use in boosted regimens for treating HIV infection. Drugs 2003;63:1299-324.
24. Highleyman L. Ritonavir manufacturing problems. Beta 1998 Oct:4.
25. Cadman J. Ritonavir users put on liquid diet. GMHC Treat Issues 1998;12:15-6.
26. Morissette SL, Soukasene S, Levinson D, Cima MJ, Almarsson O. Elucidation of crystal form diversity of the HIV protease inhibitor ritonavir by high-throughput crystallization. Proc Natl Acad Sci USA 2003;100:2180-4.
27. Diz Dios P, Ocampo Hermida A, Miralles Alvarez C, Vazquez Garcia E, Martinez Vazquez C. Regression of AIDS-related Kaposi's sarcoma following ritonavir therapy. Oral Oncol 1998;34:236-8.
28. Cattelan AM, Calabro ML, Aversa SM, Zanchetta M, Meneghetti F, De Rossi A, et al. Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome. Eur J Cancer 1999;35:1809-15.
29. Myers BD, Kessler E, Levi J, Pick A, Rosenfeld JB, Tikvah P. Kaposi sarcoma in kidney transplant recipients. Arch Intern Med 1974;133:307-11.
30. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003;348:1681-91.
31. Frisch M, Biggar RJ, Engels EA, Goedert JJ. Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001;285:1736-45.